AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $124.00
- 52-wk high
- $212.75
- High
- $130.83
- 52-wk low
- $90.39
- Low
- $121.04
- Prev close
- $124.89
- Mkt cap
- $28.13B
- Volume
- 2.84M
- Fwd P/E
- 76.9x
- Beta
- 0.82
- P/S
- 24.7x
- P/B
- 36.0x
- Profit margin
- -76.9%
- Op margin
- -23.8%
- ROE
- -87.2%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Earnings
Earnings came in 24.6% above what analysts expected.
Earnings per share
-$0.69 expected
Revenue
$393.4M expected
The release did not provide a source-backed EPS figure.
FY2026 guidance
$1.25B to $1.40B
No comparable estimate
Reports Oct 29, 2026, in 49 days
EPS expected
-$0.90 to $0.04
Revenue expected
19 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $142.3M | $263.8M | $306.0M | $425.5M |
| Cost of what it sold | $29.4M | $44.2M | $49.5M | $67.2M |
| Gross profit | $113.0M | $219.6M | $256.5M | $358.3M |
| What it spent | ||||
| Research and development | $186.4M | $254.9M | $209.5M | $210.0M |
| Sales and admin | $186.4M | $212.5M | $247.3M | $247.5M |
| Other operating costs | $106.2M | — | — | -$97.7M |
| Total operating expenses | $479.0M | $469.3M | $456.7M | $359.8M |
| What was left | ||||
| Operating profit | -$366.0M | -$249.7M | -$200.3M | -$1.5M |
| Interest on debt | $20.4M | $20.6M | $20.1M | $20.3M |
| Profit before tax | -$368.7M | -$326.9M | -$162.1M | -$11.4M |
| Tax | $1.3M | $1.6M | $1.5M | $1.9M |
| Net profit | -$370.0M | -$328.5M | -$163.6M | -$13.2M |
| EBITDA | -$345.7M | -$302.1M | -$136.3M | $14.2M |
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
55 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Insmed to Present Data across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
BullishSep 4Insmed Grants Inducement Awards to 128 New Employees
NeutralSep 4Insmed (INSM) Q1 2025 Earnings: Results, Market Reaction & History
Leans bullishSep 4Insmed director Sharoky sells $637,650 of Insmed stock
NeutralSep 3Brinsupri/Brensocatib Approved for Bronchiectasis in Japan
BullishAug 26Insmed director Melvin Sharoky sells $637,650 in shares
BullishAug 26
Macro
11 macro signals shaping INSM right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results